{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T09:31:30Z","timestamp":1782293490001,"version":"3.54.5"},"reference-count":68,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T00:00:00Z","timestamp":1647475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>This review was designed to discuss the emerging and current pharmacotherapeutic agents for the treatment of Lassa viral haemorrhagic fever disease (LVHFD), also known as Lassa fever (LF). Original peer-reviewed articles that investigated LF were identified using the Medline Entrez-PubMed search. Information was also sourced from printed textbooks and reports by recognized health professional bodies such as the WHO, CDC, the Nigerian Federal Ministry of Health and the United Nations Children\u2019s Fund (UNICEF). A total of 103 articles were reviewed and 78 were found to contain information relevant to the study.<\/jats:p>\n               <jats:p>LF remains an endemic disease of public health concern in the West Africa region, and in the rest of the world as cases have been imported into non-endemic regions as well. Currently, there are no approved vaccines or therapeutics for the treatment of Lassa mammarenavirus (LASV) infection. There are, however, off-label therapeutics being used (ribavirin and convalescent plasma) whose efficacy is suboptimal. Research is still ongoing on possible therapeutic options and drug repurposing of therapeutic agents currently in use for other clinical conditions. Considered therapeutic options include favipiravir, taribavirin, Arevirumab-3 and experimental drugs such as losmapimod, adamantyl diphenyl piperazine 3.3, Arbidol (umifenovir) and decanoyl-RRLL-chloromethyl ketone (dec-RRLL-CMK).<\/jats:p>\n               <jats:p>Current treatments for LF are limited, hence the institution of mitigating measures to prevent infection is of utmost importance and should be prioritized, especially in endemic regions. Heightened searches for other therapeutic options with greater efficacy and lower toxicity are still ongoing, as well as for vaccines as the absence of these classifies the disease as a priority disease of high public health impact.<\/jats:p>","DOI":"10.1093\/jac\/dkac064","type":"journal-article","created":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T20:10:24Z","timestamp":1647375024000},"page":"1525-1531","source":"Crossref","is-referenced-by-count":11,"title":["Contemporary and emerging pharmacotherapeutic agents for the treatment of Lassa viral haemorrhagic fever disease"],"prefix":"10.1093","volume":"77","author":[{"given":"Adejoke Adijat","family":"Joseph","sequence":"first","affiliation":[{"name":"Department of Microbial Pathology, University of Medical Sciences , Ondo, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8761-1709","authenticated-orcid":false,"given":"Olumuyiwa John","family":"Fasipe","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Therapeutics, University of Medical Sciences , Ondo, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluyemi Adesoji","family":"Joseph","sequence":"additional","affiliation":[{"name":"Department of Sociology, Nelson Mandela University , Port Elizabeth, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olalekan Aliu","family":"Olatunji","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Parasitology, University College Hospital , Ibadan, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,3,17]]},"reference":[{"key":"2022053122481401600_dkac064-B1","article-title":"Lassa fever","author":"CDC"},{"key":"2022053122481401600_dkac064-B2","article-title":"Lassa","author":"Viral Hemorrhagic Fever Consortium (VHFC)"},{"key":"2022053122481401600_dkac064-B3","article-title":"Lassa fever","author":"MedicineNet"},{"key":"2022053122481401600_dkac064-B4","doi-asserted-by":"crossref","first-page":"6992","DOI":"10.1128\/JVI.74.15.6992-7004.2000","article-title":"Genetic diversity among Lassa virus strains","volume":"74","author":"Bowen","year":"2000","journal-title":"J Virol"},{"key":"2022053122481401600_dkac064-B5","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1093\/infdis\/155.3.456","article-title":"Clinical virology of Lassa fever in hospitalized patients","volume":"155","author":"Johnson","year":"1987","journal-title":"J Infect Dis"},{"key":"2022053122481401600_dkac064-B6","doi-asserted-by":"crossref","first-page":"198000","DOI":"10.1016\/j.virusres.2020.198000","article-title":"Prevalence and outcome of Lassa fever among hospitalized patients in Ebonyi State, Nigeria, 2018-2019","volume":"285","author":"Nwafor","year":"2020","journal-title":"Virus Res"},{"key":"2022053122481401600_dkac064-B7","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1136\/bmj.311.7009.857","article-title":"Review of cases of nosocomial Lassa fever in Nigeria: the high price of poor medical practice","volume":"311","author":"Fisher-Hoch","year":"1995","journal-title":"Br Med J"},{"key":"2022053122481401600_dkac064-B8","article-title":"National Guidelines for Lassa Fever Case Management","author":"Nigeria Centre for Disease Control (NCDC)"},{"key":"2022053122481401600_dkac064-B9","doi-asserted-by":"crossref","first-page":"407","DOI":"10.4269\/ajtmh.1988.38.407","article-title":"Viral hemorrhagic fever antibodies in Nigerian populations","volume":"38","author":"Tomori","year":"1988","journal-title":"Am J Trop Med Hyg"},{"key":"2022053122481401600_dkac064-B10","article-title":"On the trail of Lassa fever in Southern Nigeria","author":"WHO"},{"key":"2022053122481401600_dkac064-B11","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4103\/mjdrdypu.mjdrdypu_5_19","article-title":"The observed seasonal variation pattern and changing epidemiology of Lassa viral hemorrhagic fever disease in Ondo State, Nigeria","volume":"13","author":"Osho","year":"2020","journal-title":"Med J DY Patil Vidyapeeth"},{"key":"2022053122481401600_dkac064-B12","doi-asserted-by":"crossref","first-page":"e0009788","DOI":"10.1371\/journal.pntd.0009788","article-title":"Clinical characterization of Lassa fever: a systematic review of clinical reports and research to inform clinical trial design","volume":"15","author":"Merson","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"key":"2022053122481401600_dkac064-B13","first-page":"86","article-title":"Update on Lassa fever in West Africa","volume":"10","author":"WHO","year":"2005","journal-title":"Wkly Epidemiol Rec"},{"key":"2022053122481401600_dkac064-B14","doi-asserted-by":"crossref","first-page":"780","DOI":"10.4269\/ajtmh.1973.22.780","article-title":"Clinical presentation of Lassa fever cases during the hospital epidemic at Zorzor, Liberia, March\u2013April 1972","volume":"22","author":"Mertens","year":"1973","journal-title":"Am J Trop Med Hyg"},{"key":"2022053122481401600_dkac064-B15","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.2147\/DDDT.S147276","article-title":"Current research for a vaccine against Lassa hemorrhagic fever virus","volume":"12","author":"Warner","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"2022053122481401600_dkac064-B16","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.3390\/v4112514","article-title":"Advanced vaccine candidates for Lassa fever","volume":"4","author":"Lukashevich","year":"2012","journal-title":"Viruses"},{"key":"2022053122481401600_dkac064-B17","article-title":"Lassa fever: origins, reservoirs, transmission and guidelines","author":"Public Health England"},{"key":"2022053122481401600_dkac064-B18","first-page":"372","article-title":"Understanding Lassa fever virus and diversification of the rodent vector in the Tropics","volume":"4","author":"Thairu","year":"2015","journal-title":"Int J Curr Med Res"},{"key":"2022053122481401600_dkac064-B19","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.3201\/eid1212.060812","article-title":"Mastomys natalensis and Lassa fever, West Africa","volume":"12","author":"Lecompte","year":"2006","journal-title":"Emerg Infect Dis"},{"key":"2022053122481401600_dkac064-B20","first-page":"1","article-title":"Lassa fever in West African sub-region: an overview","volume":"44","author":"Ogbu","year":"2007","journal-title":"J Vector Borne Dis"},{"key":"2022053122481401600_dkac064-B21","first-page":"894","article-title":"Imported Lassa fever - New Jersey, 2004","volume":"53","author":"CDC","year":"2004","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2022053122481401600_dkac064-B22","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1093\/infdis\/158.4.872","article-title":"An imported case of Lassa fever with late appearance of polyserositis","volume":"158","author":"Hirabayashi","year":"1988","journal-title":"J Infect Dis"},{"key":"2022053122481401600_dkac064-B23","article-title":"Lassa mammarenavirus","author":"Wikipedia"},{"key":"2022053122481401600_dkac064-B24","doi-asserted-by":"crossref","first-page":"e53273","DOI":"10.1371\/journal.pone.0053273","article-title":"LCMV glycosylation modulates viral fitness and cell tropism","volume":"8","author":"Bonhomme","year":"2013","journal-title":"PLoS One"},{"key":"2022053122481401600_dkac064-B25","doi-asserted-by":"crossref","first-page":"12701","DOI":"10.1073\/pnas.221447598","article-title":"The Lassa virus glycoprotein precursor GP-C is proteolytically processed by subtilase SKI-1\/S1P","volume":"98","author":"Lenz","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"2022053122481401600_dkac064-B26","doi-asserted-by":"crossref","first-page":"e1002232","DOI":"10.1371\/journal.ppat.1002232","article-title":"Old World arenaviruses enter the host cell via the multivesicular body and depend on the endosomal sorting complex required for transport","volume":"7","author":"Pasqual","year":"2011","journal-title":"PLoS Pathogens"},{"key":"2022053122481401600_dkac064-B27","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1128\/JVI.06451-11","article-title":"Identification of cell surface molecules involved in dystroglycan-independent Lassa virus cell entry","volume":"86","author":"Shimojima","year":"2012","journal-title":"J Virol"},{"key":"2022053122481401600_dkac064-B28","article-title":"Lassa Hemorrrhagic Fever","author":"Infection Landscapes"},{"key":"2022053122481401600_dkac064-B29","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/bs.ircmb.2020.09.003","article-title":"TAM receptors: a phosphatidylserine receptor family and its implications in viral infections","volume":"357","author":"Roy","year":"2020","journal-title":"Int Rev Cell Mol Biol"},{"key":"2022053122481401600_dkac064-B30","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.3390\/v4112766","article-title":"Immune responses and Lassa virus infection","volume":"4","author":"Russier","year":"2012","journal-title":"Viruses"},{"key":"2022053122481401600_dkac064-B31","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3390\/pathogens8010017","article-title":"Virus\u2013host interactions involved in Lassa virus entry and genome replication","volume":"8","author":"Loureiro","year":"2019","journal-title":"Pathogens"},{"key":"2022053122481401600_dkac064-B32","doi-asserted-by":"crossref","first-page":"e1007430","DOI":"10.1371\/journal.ppat.1007430","article-title":"Lassa virus activates myeloid dendritic cells but suppresses their ability to stimulate T cells","volume":"14","author":"Schaeffer","year":"2018","journal-title":"PLoS Pathog"},{"key":"2022053122481401600_dkac064-B33","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1136\/bmj.327.7426.1271","article-title":"Lassa fever: epidemiology, clinical features, and social consequences","volume":"327","author":"Richmond","year":"2003","journal-title":"BMJ"},{"key":"2022053122481401600_dkac064-B34","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.3390\/v13071187","article-title":"Progress in anti-mammarenavirus drug development","volume":"13","author":"Kim","year":"2021","journal-title":"Viruses"},{"key":"2022053122481401600_dkac064-B35","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJM198601023140104","article-title":"Lassa fever. Effective therapy with ribavirin","volume":"314","author":"McCormick","year":"1986","journal-title":"N Engl J Med"},{"key":"2022053122481401600_dkac064-B36","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1472-6807-11-47","article-title":"Docking studies on novel analogues of 8 methoxy fluoroquinolones against GyrA mutants of Mycobacterium tuberculosis","volume":"11","author":"Anand","year":"2011","journal-title":"BMC Struct Biol"},{"key":"2022053122481401600_dkac064-B37","doi-asserted-by":"crossref","first-page":"11693","DOI":"10.1038\/s41598-017-10198-0","article-title":"Determining ribavirin\u2019s mechanism of action against Lassa virus infection","volume":"7","author":"Carrillo-Bustamante","year":"2017","journal-title":"Sci Rep"},{"key":"2022053122481401600_dkac064-B38","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1086\/657315","article-title":"Review of the literature and proposed guidelines for the use of oral ribavirin as postexposure prophylaxis for Lassa fever","volume":"51","author":"Bausch","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2022053122481401600_dkac064-B39","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ijid.2019.07.015","article-title":"Ribavirin for the treatment of Lassa fever: a systematic review and meta-analysis","volume":"87","author":"Eberhardt","year":"2019","journal-title":"Int J Infect Dis"},{"key":"2022053122481401600_dkac064-B40","first-page":"435","article-title":"Lassa immune serum","volume":"55","author":"Clayton","year":"1977","journal-title":"Bull World Health Organ"},{"key":"2022053122481401600_dkac064-B41","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0035-9203(84)90107-X","article-title":"The use of Lassa fever convalescent plasma in Nigeria","volume":"78","author":"Frame","year":"1984","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2022053122481401600_dkac064-B42","doi-asserted-by":"crossref","first-page":"107512","DOI":"10.1016\/j.pharmthera.2020.107512","article-title":"Favipiravir, an anti-influenza drug against life-threatening RNA virus infections","volume":"209","author":"Shiraki","year":"2020","journal-title":"Pharmacol Ther"},{"key":"2022053122481401600_dkac064-B43","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.3201\/eid2409.180233","article-title":"Use of favipiravir to treat Lassa virus infection in macaques","volume":"24","author":"Rosenke","year":"2018","journal-title":"Emerg Infect Dis"},{"key":"2022053122481401600_dkac064-B44","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/cid\/cix406","article-title":"Favipiravir and ribavirin treatment of epidemiologically linked cases of Lassa fever","volume":"65","author":"Raabe","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2022053122481401600_dkac064-B45","doi-asserted-by":"crossref","first-page":"e6834","DOI":"10.1371\/journal.pone.0068347","article-title":"The ambiguous base-pairing and high substrate efficiency of T-705 (favipiravir) ribofuranosyl 5\u2032-triphosphate towards influenza A virus polymerase","volume":"8","author":"Jin","year":"2013","journal-title":"PLoS One"},{"key":"2022053122481401600_dkac064-B46","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2183\/pjab.93.027","article-title":"Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase","volume":"93","author":"Furuta","year":"2017","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"2022053122481401600_dkac064-B47","doi-asserted-by":"crossref","first-page":"e1008535","DOI":"10.1371\/journal.pcbi.1008535","article-title":"Lassa viral dynamics in non-human primates treated with favipiravir or ribavirin","volume":"17","author":"Lingas","year":"2021","journal-title":"PLoS Comput Biol"},{"key":"2022053122481401600_dkac064-B48","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1021\/jm00266a014","article-title":"Synthesis and antiviral activity of 1,2,4-triazole-3-thiocarboxamide and 1,2,4-triazole-3-carboxamidine ribonucleosides","volume":"16","author":"Witkowski","year":"1973","journal-title":"J Med Chem"},{"key":"2022053122481401600_dkac064-B49","first-page":"1585","article-title":"Viramidine (Ribapharm)","volume":"3","author":"Barnard","year":"2002","journal-title":"Curr Opin Investig Drugs"},{"key":"2022053122481401600_dkac064-B50","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/jmv.1890120203","article-title":"Protection of Lassa virus-infected guinea pigs with Lassa-immune plasma of guinea pig, primate, and human origin","volume":"12","author":"Jahrling","year":"1983","journal-title":"J Med Virol"},{"key":"2022053122481401600_dkac064-B51","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.coviro.2019.07.003","article-title":"Antibody therapy for Lassa fever","volume":"37","author":"Cross","year":"2019","journal-title":"Curr Opin Virol"},{"key":"2022053122481401600_dkac064-B52","first-page":"343","article-title":"Induction of apoptosis and inhibition of cell growth are independent responses to interferon-\u03b1 in hematopoietic cell lines","volume":"8","author":"Sangfelt","year":"1997","journal-title":"Cell Growth Differ"},{"key":"2022053122481401600_dkac064-B53","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1016\/S0168-8278(03)00207-1","article-title":"Mechanisms of action of interferon and nucleoside analogues","volume":"39","author":"Thomas","year":"2003","journal-title":"J Hepatol"},{"key":"2022053122481401600_dkac064-B54","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.antiviral.2019.03.014","article-title":"Identification of a clinical compound losmapimod that blocks Lassa virus entry","volume":"167","author":"Zhang","year":"2019","journal-title":"Antiviral Res"},{"key":"2022053122481401600_dkac064-B55","doi-asserted-by":"crossref","first-page":"e1007439","DOI":"10.1371\/journal.ppat.1007439","article-title":"A potent Lassa virus antiviral targets an arenavirus virulence determinant","volume":"14","author":"Madu","year":"2018","journal-title":"PLoS Pathog"},{"key":"2022053122481401600_dkac064-B56","doi-asserted-by":"crossref","first-page":"8381","DOI":"10.1128\/JVI.01289-16","article-title":"Correction for Ngo, et al., Identification and mechanism of action of a novel small-molecule inhibitor of arenavirus multiplication","volume":"90","author":"Ngo","year":"2016","journal-title":"J Virol"},{"key":"2022053122481401600_dkac064-B57","doi-asserted-by":"crossref","first-page":"104701","DOI":"10.1016\/j.antiviral.2019.104701","article-title":"The antifungal isavuconazole inhibits the entry of lassa virus by targeting the stable signal peptide-GP2 subunit interface of lassa virus glycoprotein","volume":"174","author":"Zhang","year":"2020","journal-title":"Antivir Res"},{"key":"2022053122481401600_dkac064-B58","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1073\/pnas.1116051110","article-title":"Small molecule targeting Cdc42-intersectin interaction disrupts Golgi organization and suppresses cell motility","volume":"110","author":"Friesland","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"2022053122481401600_dkac064-B59","doi-asserted-by":"crossref","first-page":"e1007322","DOI":"10.1371\/journal.ppat.1007322","article-title":"Critical role for cholesterol in Lassa fever virus entry identified by a novel small molecule inhibitor targeting the viral receptor LAMP1","volume":"14","author":"Wang","year":"2018","journal-title":"PLoS Pathog"},{"key":"2022053122481401600_dkac064-B60","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3390\/v10040184","article-title":"Arbidol (umifenovir): a broad-spectrum antiviral drug that inhibits medically important arthropod-borne flaviviruses","volume":"10","author":"Haviernik","year":"2018","journal-title":"Viruses"},{"key":"2022053122481401600_dkac064-B61","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.antiviral.2018.10.011","article-title":"Tangeretin, an extract from citrus peels, blocks cellular entry of arenaviruses that cause viral hemorrhagic fever","volume":"160","author":"Tang","year":"2018","journal-title":"Antivir Res"},{"key":"2022053122481401600_dkac064-B62","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nature13027","article-title":"Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430","volume":"508","author":"Warren","year":"2014","journal-title":"Nature"},{"key":"2022053122481401600_dkac064-B63","doi-asserted-by":"crossref","first-page":"105180","DOI":"10.1016\/j.antiviral.2021.105180","article-title":"An update on the progress of galidesivir (BCX4430), a broad-spectrum antiviral","volume":"195","author":"Julander","year":"2021","journal-title":"Antiviral Res"},{"key":"2022053122481401600_dkac064-B64","doi-asserted-by":"crossref","first-page":"8019","DOI":"10.1021\/acs.jmedchem.6b00794","article-title":"Identification of inhibitors for the DEDDh family of exonucleases and a unique inhibition mechanism by crystal structure analysis of CRN-4 bound with 2-morpholin-4-ylethanesulfonate (MES)","volume":"59","author":"Huang","year":"2016","journal-title":"J Med Chem"},{"key":"2022053122481401600_dkac064-B65","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1073\/pnas.1016404108","article-title":"Structure of the Lassa virus nucleoprotein reveals a dsRNA-specific 3\u2032 to 5\u2032 exonuclease activity essential for immune suppression","volume":"108","author":"Hastie","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"2022053122481401600_dkac064-B66","doi-asserted-by":"crossref","first-page":"23471","DOI":"10.1074\/jbc.M513675200","article-title":"The proprotein convertase SKI-1\/S1P. In vitro analysis of Lassa virus glycoprotein-derived substrates and ex vivo validation of irreversible peptide inhibitors","volume":"281","author":"Pasquato","year":"2006","journal-title":"J Biol Chem"},{"key":"2022053122481401600_dkac064-B67","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1128\/JVI.02019-10","article-title":"Antiviral activity of a small-molecule inhibitor of arenavirus glycoprotein processing by the cellular site 1 protease","volume":"85","author":"Urata","year":"2011","journal-title":"J Virol"},{"key":"2022053122481401600_dkac064-B68","doi-asserted-by":"crossref","first-page":"4578","DOI":"10.1128\/JVI.06604-11","article-title":"The PI3K\/Akt pathway contributes to arenavirus budding","volume":"86","author":"Urata","year":"2012","journal-title":"J Virol"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/6\/1525\/43893351\/dkac064.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/6\/1525\/43893351\/dkac064.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T22:49:50Z","timestamp":1654037390000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/77\/6\/1525\/6549754"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,17]]},"references-count":68,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,3,17]]},"published-print":{"date-parts":[[2022,5,29]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkac064","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,6,1]]},"published":{"date-parts":[[2022,3,17]]}}}